Advertisement
U.S. Markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4791-0.0046 (-0.95%)
At close: 04:00PM EDT
0.4997 +0.02 (+4.30%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close0.4837
Open0.4895
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4300 - 0.5300
52 Week Range0.2790 - 2.4200
Volume414,123
Avg. Volume395,545
Market Cap9.226M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-0.2800
Earnings DateFeb 29, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VIRI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virios Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/10/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

    - New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms – ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a develo

  • GlobeNewswire

    Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

    ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023. Key Highlights and Upcoming Milestones Virios received written communication from the Food and Drug Administration (“FDA”

  • GlobeNewswire

    Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

    ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024. Dear Virios (VIRI) Shareholders, On behalf of the Virios directors and the executive team, we would like to provid